Johnson & Johnson on Feb. 18 announced it would invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery, Pennsylvania, that will create new medicines to treat cancer, and neurological and immune-related diseases.
The facility expands upon Johnson & Johnson’s extensive footprint in the Commonwealth of Pennsylvania, where it operates 10 facilities spanning more than 2 million square feet. Johnson & Johnson subsidiary Janssen Biotech will operate the new facility in Lower Gwynedd Township in Montgomery County, north of downtown Philadelphia.
